Seelos Therapeutics ROA 2006-2021 | SEEL

Current and historical return on assets (ROA) values for Seelos Therapeutics (SEEL) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Seelos Therapeutics ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2021-06-30 $-0.04B $0.09B -96.20%
2021-03-31 $-0.03B $0.04B -173.68%
2020-12-31 $-0.02B $0.02B -155.10%
2020-09-30 $-0.02B $0.01B -223.26%
2020-06-30 $-0.02B $0.01B -187.76%
2020-03-31 $-0.02B $0.01B -164.71%
2019-12-31 $-0.05B $0.01B -424.49%
2019-09-30 $-0.04B $0.02B -442.11%
2019-06-30 $-0.04B $0.01B -571.43%
2019-03-31 $-0.04B $0.01B -608.00%
2018-12-31 $-0.00B $0.00B -63.16%
2018-09-30 $-0.00B $0.01B -61.54%
2018-06-30 $-0.01B $0.01B -96.55%
2018-03-31 $-0.01B $0.01B -103.23%
2017-12-31 $0.00B $0.01B 13.33%
2017-09-30 $0.00B $0.01B 42.86%
2017-06-30 $0.01B $0.01B 88.89%
2017-03-31 $0.00B $0.01B 66.67%
2016-12-31 $-0.01B $0.01B -96.55%
2016-09-30 $-0.01B $0.01B -112.50%
2016-06-30 $-0.01B $0.01B -152.94%
2016-03-31 $-0.02B $0.01B -153.85%
2015-12-31 $-0.02B $0.01B -146.94%
2015-09-30 $-0.03B $0.01B -235.71%
2015-06-30 $-0.03B $0.01B -187.88%
2015-03-31 $-0.02B $0.02B -128.00%
2014-12-31 $-0.02B $0.02B -105.00%
2014-09-30 $-0.01B $0.02B -22.73%
2014-06-30 $-0.01B $0.02B -22.22%
2014-03-31 $-0.01B $0.03B -45.36%
2013-12-31 $-0.02B $0.02B -76.40%
2013-09-30 $-0.04B $0.02B -160.00%
2013-06-30 $-0.04B $0.03B -128.44%
2013-03-31 $-0.04B $0.02B -129.73%
2012-12-31 $-0.03B $0.02B -101.59%
2012-09-30 $-0.02B $0.04B -57.14%
2012-06-30 $-0.02B $0.03B -73.91%
2012-03-31 $-0.02B $0.03B -103.90%
2011-12-31 $-0.02B $0.02B -110.77%
2011-09-30 $-0.03B $0.01B -155.22%
2011-06-30 $-0.03B $0.01B -203.77%
2011-03-31 $-0.02B $0.02B -146.03%
2010-12-31 $-0.03B $0.02B -178.46%
2010-09-30 $-0.05B $0.00B -280.60%
2010-06-30 $-0.05B $0.02B -243.24%
2010-03-31 $-0.04B $0.02B -289.66%
2009-12-31 $-0.03B $0.02B -284.44%
2009-09-30 $0.00B $0.01B 0.00%
2009-06-30 $-0.00B $0.01B -23.53%
2009-03-31 $0.00B $0.01B 10.81%
2008-12-31 $-0.00B $0.01B -21.62%
2008-09-30 $-0.01B $0.01B -61.54%
2008-06-30 $-0.01B $0.01B -47.62%
2008-03-31 $-0.01B $0.01B -81.82%
2007-12-31 $-0.01B $0.01B -67.92%
2007-09-30 $-0.01B $0.01B -51.61%
2007-06-30 $-0.01B $0.01B -49.23%
2007-03-31 $-0.01B $0.02B -41.18%
2006-12-31 $-0.01B $0.02B -47.06%
2006-09-30 $-0.01B $0.01B -59.02%
2006-06-30 $-0.01B $0.02B -62.50%
2006-03-31 $-0.01B $0.02B -88.89%
2005-12-31 $-0.02B $0.01B -106.67%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.240B $0.000B
Seelos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the development and advancement of novel therapeutics to address unmet medical needs for central nervous system disorders. The company's product pipeline consists of SLS-002, SLS-006, SLS-008, SLS-010 and SLS-012 which are in clinical stage. Seelos Therapeutics Inc., formerly known as Apricus Biosciences Inc., is based in New York, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76